A phase I clinical trial of AN2-502998 for treatment of chronic Chagas disease
Latest Information Update: 07 May 2025
At a glance
- Drugs AN2 502998 (Primary)
- Indications Chagas disease
- Focus Adverse reactions; First in man
Most Recent Events
- 01 May 2025 According to AN2 Therapeutics media release, the company has initiated start up activities for this study in healthy volunteers, and expects to complete this study in 2H 2025.
- 13 Nov 2024 According to a AN2 Therapeutics media release, company plans to initiate Phase 1 clinical development with AN2-502998 in mid-2025.
- 16 Aug 2024 New trial record